← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,306	+60	+5%	$72.6B
2	2 Danaher DHR $158B	1,207	+7	+0.6%	$53.4B
3	3 Novartis NVS $279B	1,013	+6	+0.6%	$20.7B
4	4 Agilent Technologies A $49.1B	692	+40	+6%	$18.4B
5	5 Illumina ILMN $41B	692	+48	+7%	$31.8B
6	6 Regeneron Pharmaceuticals REGN $80.1B	620	-19	-3%	$24.9B
7	7 Revvity RVTY $17B	375	-23	-6%	$7.91B
8	8 Charles River Laboratories CRL $14.4B	333	-6	-2%	$5.03B
9	9 Ionis Pharmaceuticals IONS $7.1B	326	+10	+3%	$5.08B
10	10 DELISTED bluebird bio BLUE	303	+7	+2%	$9B
11	11 Alnylam Pharmaceuticals ALNY $30B	293	+11	+4%	$10.9B
12	12 DELISTED CATALENT, INC. CTLT	274	-2	-0.7%	$5.55B
13	13 Sarepta Therapeutics SRPT $1.78B	269	+15	+6%	$4.2B
14	14 Myriad Genetics MYGN $397M	260	+10	+4%	$2.22B
15	15 Qiagen QGEN $9.41B	231	+16	+7%	$4.6B
16	16 Bruker BRKR $8.47B	227	-6	-3%	$3.18B
17	17 Azenta AZTA $1.63B	220	+3	+1%	$1.85B
18	18 DELISTED SANGAMO THERAPEUTICS INC SGMO	208	+38	+22%	$1.09B
19	19 Editas Medicine EDIT $349M	197	+46	+30%	$1.03B
20	20 Precigen PGEN $2.64B	166	+3	+2%	$1.66B
21	21 Ultragenyx Pharmaceutical RARE $1.47B	165	+2	+1%	$2.5B
22	22 PTC Therapeutics PTCT $4.98B	148	+23	+18%	$1.15B
23	23 CRISPR Therapeutics CRSP $4.86B	135	+52	+63%	$855M
24	24 Intellia Therapeutics NTLA $1.6B	130	+18	+16%	$557M
25	25 Regenxbio RGNX $454M	120	+12	+11%	$668M